TEGA THERAPEUTICS INC
La Jolla, CA · Biotech · Private
Intracerebroventricular enzyme replacement therapy for GM1 gangliosidosis using beta-galactosidase delivered directly to the brain
tegatherapeutics.com →- Grants
- $5.2M
- 13 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 14
- 2 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Intranasal Sulfamidase Delivery to the Brain | $237,138 | |
| Federal grant | National Science Foundation · Phase I · STTR Phase I: Biomanufacture of Novel Heparan Sulfate Glycosaminoglycans | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Intracerebroventricular Iduronidase Delivery to the Brain | $225,000 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Bioengineered Recombinant Anticoagulant Heparin | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Intracerebroventricular alpha-N-acetylglucosaminidase Delivery to the Brain | $225,254 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Development of Bioengineered Anticoagulant Heparin from a Non-Animal Source | $1,394,931 | |
| Federal grant | Department of Health and Human Services · Phase I · Title: Intracerebroventricular sulfamidase delivery to the Brain | $258,169 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad | $321,866 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad | $321,866 | |
| Federal grant | Department of Health and Human Services · Phase I · Title: Development and Validation of Therapy for GM1 Gangliosidosis | $461,701 | |
| Federal grant | Department of Health and Human Services · Phase I · Title: Development and Validation of Therapy for GM1 Gangliosidosis | $461,701 | |
| Federal grant | Department of Health and Human Services · Phase I · Testing Novel Advancements to Recombinant Heparin Production | $355,222 | |
| Federal grant | Department of Health and Human Services · Phase I · Title: New Clinical Biomarkers for GM1 Gamgliosidosis | $500,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1699 | EVOQ THERAPEUTICS, INC. | — | — |
| 1700 | OMass Therapeutics | — | — |
| 1701 | Purespring Therapeutics | — | — |
| 1702 | TEGA THERAPEUTICS INC | — | — |
| 1703 | BIOSPUTNIK LLC | — | — |
| 1704 | ONEVAX, LLC | — | — |
| 1705 | Prokaryotics, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- In Vitro Heparin And Heparan Sulfate Compositions And Methods Of Making And Usinggranted
- Heparin From Modified Mst Cells And Methods Of Making And Usingapplication
- Cellular Glycosaminoglycan Compositions And Methods Of Making And Usingapplication
- Cellular Glycosaminoglycan Compositions And Methods Of Making And Usinggranted
- Heparin And Heparan Sulfate From Modified Mast Cells And Methods Of Making And Usingapplication
- Heparin And Heparan Sulfate From Modified Mst Cells And Methods Of Making And Usingapplication
- In Vitro Heparin And Heparan Sulfate Compositions And Methods Of Making And Usingapplication
- Cellular Glycosaminoglycan Compositions And Methods Of Making And Usingapplication
- In Vitro Heparin And Heparan Sulfate Compositions And Methods Of Making And Usingapplication
- Cellular Heparan Sulfate Compositions And Methods Of Making And Usingapplication
- Heparin From Modified Mst Cells And Methods Of Making And Usingapplication
- Heparin From Modified Mst Cells And Methods Of Making And Usingapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.